Cat.No. : AAVH001Z
Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml
Serotype: AAV Serotype 8 Storage: -80 ℃
| Cat. No. | AAVH001Z |
| Description | AAV serotype 8 (AAV8) viral particles containing genome DNA of Hepatitis B virus (HBV) genotype D, serotype ayw. |
| Serotype | AAV Serotype 8 |
| Product Type | AAV viral particles |
| Application | AAV serotype 8 (AAV8) viral particles contain genomic DNA of Hepatitis B virus (HBV) genotype D, serotype ayw. These types of vectors are often used in gene therapy research and applications because of their ability to deliver genetic material into host cells. Here are some potential applications of this type of construct: Gene therapy for liver disease: Since AAV serotype 8 has a high tropism for hepatocytes, this construct can be used to deliver therapeutic genes to the liver, potentially treating inherited liver diseases such as hemophilia B, alpha-1-antitrypsin deficiency, etc. Chronic hepatitis B treatment: If the HBV element refers to a sequence from the hepatitis B virus, it may be designed to interfere with viral replication or gene expression. This hybrid vector may be used to deliver antiviral genes or RNA interference molecules that target HBV RNA. Vaccine development: The HBV component may elicit an immune response. This hybrid AAV may be used as a vaccine vector to induce immunity by including multiple antigens, not only against HBV, but also against other pathogens. Cancer therapy: Certain cancers, especially hepatocellular carcinoma (HCC), are closely associated with chronic HBV infection. This construct can be designed to deliver therapeutic genes to combat HBV-associated HCC. |
| Applications | Cell-based HBV assays, developing HBV infection mouse models |
| Insert | Genome DNA of Hepatitis B virus (HBV) genotype D, serotype ayw |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. | |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
A: There are 3 commonly used protocols for determining adenovirus titer: (1) OD260 Assay, (2) Plaque Formation Assay, and (3) End-point Dilution Assay.
A: Yes.Over the past 20 years, rAAV has been commonly used as a tool for efficient and long-term gene expression in basic research and clinical gene therapy. For example, rAAV induced transgene expression in non-human primate muscle tissue can last for more than 10 years.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Creative Biogene's AAV-HBV carries 1.3× the full-length genome of HBV, and a mouse model of persistent HBV infection can be prepared by a single tail vein injection of AAV-HBV. It has the advantages of simple preparation, high success rate, homogeneity, stability, characterization of good dose-effect relationship and wide range of applications.
The HBV-AAV mouse model has been validated for use in a wide range of HBV drug evaluations and vaccine screening.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
